All In Biotech

Drug Trial Radar · NCT07824167

The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation

Longitudinal Serum and Mucosal RSV Antibodies Following Clesrovimab (Enflonsia™, Merck) Administration in Infants During Their First Respiratory Season or [The EMBRACE Study: Enflonsia™ Monoclonal in Babies - RSV Antibody Concentration Evaluation]

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC
First posted
Sep 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, up to 8 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clesrovimab is an FDA-approved antibody drug recommended for infants younger than 8 months who are entering their first respiratory syncytial virus (RSV) season and whose mothers did not receive an RSV vaccine during pregnancy. It is given to help prevent severe RSV illness. This study will measure clesrovimab and other RSV antibodies in infants' blood and noses to learn how much of the drug reaches the nose, how long the antibodies remain, and how antibody levels change if an infant becomes infected with RSV.

Conditions

  • RSV Infection

Interventions

  • ClesrovimabBiological

    Clesrovimab (ENFLONSIA™) is a commercially available product that is administered as part of standard-of-care RSV prevention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric mean concentration (GMC) of serum RSV pre-fusion (preF) binding IgG antibodiesTime frame: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181
  2. Geometric mean concentration (GMC) of nasal RSV pre-fusion (preF) binding IgG antibodiesTime frame: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181
  3. Geometric mean titers (GMT) of serum RSV-A neutralizing antibodiesTime frame: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emory Children's Center-Vaccine Research Clinic

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.